List of Excipients in Branded Drug PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

« Back to Dashboard

Generic Drugs Containing PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
AvKARE	pioglitazone hydrochloride and metformin hydrochloride	42291-920	CARBOXYMETHYLCELLULOSE CALCIUM
AvKARE	pioglitazone hydrochloride and metformin hydrochloride	42291-920	HYDROXYPROPYL CELLULOSE
AvKARE	pioglitazone hydrochloride and metformin hydrochloride	42291-920	HYPROMELLOSE 2910
AvKARE	pioglitazone hydrochloride and metformin hydrochloride	42291-920	LACTOSE MONOHYDRATE
AvKARE	pioglitazone hydrochloride and metformin hydrochloride	42291-920	MAGNESIUM STEARATE
AvKARE	pioglitazone hydrochloride and metformin hydrochloride	42291-920	POLYETHYLENE GLYCOL 6000
AvKARE	pioglitazone hydrochloride and metformin hydrochloride	42291-920	TALC

What are the Most Frequently-Used Excipients in PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE?

# Of NDCs	Excipient
3	CARBOXYMETHYLCELLULOSE CALCIUM
3	HYDROXYPROPYL CELLULOSE
3	HYPROMELLOSE 2910
3	LACTOSE MONOHYDRATE
3	MAGNESIUM STEARATE
3	POLYETHYLENE GLYCOL 6000
3	TALC

Pioglitazone Hydrochloride and Metformin Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: October 13, 2026

Pioglitazone hydrochloride and metformin hydrochloride fixed-dose combinations are mature small-molecule products with limited compound-patent protection and substantial generic competition. The strongest commercial opportunities are differentiated immediate-release and extended-release tablets, improved gastrointestinal tolerability, lower tablet burden, manufacturing-cost reduction, and products designed for markets where type 2 diabetes prevalence is rising.

The formulation challenge is asymmetric: metformin hydrochloride is a high-dose, highly water-soluble drug with gastrointestinal tolerability constraints, while pioglitazone hydrochloride is a lower-dose, poorly water-soluble drug with different dissolution and content-uniformity requirements. The excipient system must accommodate both active ingredients without compromising bioequivalence, stability, manufacturability, or regulatory simplicity.

What is the commercial status of pioglitazone and metformin fixed-dose combinations?

Pioglitazone/metformin hydrochloride is an established type 2 diabetes combination marketed in immediate-release and extended-release forms. The U.S. reference product is Actoplus Met, with Actoplus Met XR representing the extended-release product category. The products combine an insulin-sensitizing thiazolidinedione with a biguanide that reduces hepatic glucose production.

Product category	Typical strengths	Dosage form	Commercial role
Pioglitazone/metformin immediate release	15/500 mg, 15/850 mg; other market-specific strengths	Film-coated tablet	Lower-cost generic replacement for separate tablets
Pioglitazone/metformin extended release	Strengths vary by market and product	Modified-release tablet	Reduced dosing frequency and potentially improved metformin tolerability
Separate pioglitazone and metformin tablets	Multiple strengths	Immediate- or extended-release tablets	Primary substitute and titration option
Other metformin combinations	Metformin with DPP-4, SGLT2, GLP-1 and sulfonylurea products	Multiple forms	Competitive pressure from newer diabetes therapies

The combination remains commercially relevant where low acquisition cost, insulin sensitization, and access to established oral therapy are important. It faces pressure from SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and newer combination products. Pioglitazone’s association with weight gain, edema, bone-fracture risk, and heart-failure warnings limits its positioning in some patient populations.[1]

What excipient problems must a pioglitazone/metformin formulation solve?

The formulation must solve four technical problems:

1. Metformin requires a large drug load, often making tablet size and compressibility difficult.
2. Metformin’s high water solubility can produce rapid dissolution and gastrointestinal exposure.
3. Pioglitazone has lower dose requirements but poorer aqueous solubility and different wetting behavior.
4. The two drugs can respond differently to granulation, lubrication, compression, and coating conditions.

Metformin hydrochloride excipient requirements

Metformin hydrochloride is highly soluble and typically represents most of the tablet mass. Relevant excipient functions include:

Formulation objective	Useful excipient classes	Commercial rationale
Improve flow and die filling	Colloidal silicon dioxide, pregelatinized starch, silicified microcrystalline cellulose	Supports high-dose manufacturing
Improve compactability	Microcrystalline cellulose, copovidone, povidone, starch-based binders	Reduces capping and friability
Control immediate-release disintegration	Croscarmellose sodium, crospovidone, sodium starch glycolate	Supports rapid and reproducible breakup
Moderate release rate	Hypromellose, hydrophilic matrix polymers, controlled porosity systems	Useful for extended-release metformin
Reduce sticking	Magnesium stearate, sodium stearyl fumarate, talc	Supports high-speed tableting
Improve swallowability	Film coating polymers and plasticizers	Important because metformin tablets can be large

Excessive lubricant use can reduce tablet strength and alter wetting. Hydrophobic coating or over-lubrication can also delay metformin dissolution. The formulation should establish a controlled lubrication endpoint rather than rely only on fixed blending time.

Pioglitazone hydrochloride excipient requirements

Pioglitazone hydrochloride is present at a much lower dose than metformin. The main technical risks are content uniformity, poor wetting, and segregation from the high-dose metformin fraction.

Appropriate excipient functions include:

• Wetting agents to improve dispersion of pioglitazone hydrochloride.
• Hydrophilic binders to improve granule uniformity.
• Particle-size engineering or co-milling to reduce segregation.
• Solubilizing or surfactant systems where justified by dissolution data.
• Fine-particle carrier systems to distribute the low-dose active across the metformin matrix.

Sodium lauryl sulfate may improve wetting, but its concentration must be controlled because it can affect dissolution, gastrointestinal tolerability, and tablet processing. Polysorbates and other surfactants may be technically useful but can create stability and impurity-control issues.

What excipient platforms are best for immediate-release tablets?

The most practical immediate-release platform is a conventional wet-granulated or dry-granulated tablet with separate control of the high-dose and low-dose drug fractions.

Option 1: Single-blend direct compression

A single-blend formulation is the lowest-cost approach. It can use microcrystalline cellulose, crospovidone or croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate or sodium stearyl fumarate.

Its principal risk is low-dose pioglitazone segregation during transfer and compression. Direct compression is commercially attractive only when particle-size distribution, bulk density, blending order, and hopper residence time are tightly controlled.

Option 2: Wet granulation

Wet granulation provides stronger control over flow, compressibility, and content uniformity. Povidone, copovidone, hydroxypropyl cellulose, or starch-based binders can be evaluated.

A practical design is to granulate the pioglitazone fraction with part of the metformin and binder, then blend with the remaining metformin and extragranular disintegrant. This approach can reduce segregation but increases drying energy, process steps, and degradation risk.

Option 3: Dry granulation or roller compaction

Roller compaction is attractive where water exposure is undesirable or where continuous manufacturing is targeted. It can reduce processing time and solvent use. The main risks are ribbon-density variability, loss of compactability after milling, and changes in dissolution caused by excessive densification.

For a mature generic product, dry granulation may provide a cost advantage if it produces acceptable bioequivalence and tablet robustness without a complex coating system.

What excipients are best for extended-release pioglitazone/metformin tablets?

Extended-release products should prioritize metformin release control. Pioglitazone generally does not require the same high-dose release-management system, which creates a design choice.

Hydrophilic matrix tablets

Hypromellose is the most established matrix polymer for extended-release metformin. Polymer viscosity, substitution grade, particle size, and concentration control the initial gel layer and subsequent diffusion and erosion.

A high-viscosity hypromellose matrix may reduce the risk of dose dumping but can create:

• Incomplete release at later time points.
• Large tablet dimensions.
• Sensitivity to compression force.
• Greater dependence on gastrointestinal hydrodynamics.

Low- to medium-viscosity polymer blends can provide a more manageable release profile but require stronger control of porosity and tablet hardness.

Bilayer or multilayer tablets

A bilayer tablet can separate formulation functions:

• One layer for immediate or controlled pioglitazone delivery.
• One matrix layer for extended-release metformin.

Bilayer technology can improve segregation control and enable independent optimization. It also raises manufacturing complexity, including layer weight variation, interfacial adhesion, delamination, and specialized equipment requirements.

Coated matrix tablets

A film-coated matrix tablet offers a relatively simple commercial platform. The coat can improve swallowability and appearance but should not be treated as the primary release-control mechanism unless the product is specifically designed as a membrane-controlled system.

Ethylcellulose, cellulose acetate, hypromellose, polyethylene glycol, talc, and titanium dioxide are common functional or nonfunctional coating components. Regulatory and supply-chain teams should account for titanium dioxide restrictions in some jurisdictions and for changing excipient policies in export markets.

How should excipient selection address metformin gastrointestinal tolerability?

Metformin-related nausea, diarrhea, abdominal discomfort, and bloating are major formulation considerations. Extended-release technology can improve tolerability for some patients by reducing rapid luminal exposure, although the clinical effect depends on the complete dosage-form design.

The most commercially defensible approaches are:

• Hydrophilic matrix release with controlled early dissolution.
• Reduced peak exposure without compromising total drug release.
• Tablet-size reduction through higher-density granulation.
• Use of a bilayer design to separate immediate and controlled release.
• Robust dissolution specifications across pH conditions.
• Low-variability manufacturing that avoids dose dumping.

Enteric coating is generally a weak first-line strategy for metformin because delayed release can shift drug exposure and complicate bioequivalence. It may be relevant to specific gastrointestinal targeting concepts, but it adds regulatory and clinical risk.

What FDA regulatory pathway applies to generic products?

A conventional generic product would normally use the abbreviated new drug application pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must demonstrate pharmaceutical equivalence and bioequivalence to the applicable reference product.[2]

For immediate-release combination tablets, the principal development requirements include:

• Matching active ingredients and labeled strengths.
• Demonstrating comparative dissolution.
• Establishing content uniformity and assay.
• Conducting bioequivalence studies where required.
• Providing stability data.
• Addressing formulation-specific inactive-ingredient concerns.
• Certifying against relevant Orange Book patents through the ANDA pathway.

Extended-release products generally carry greater development risk because in vitro release, food effects, alcohol effects, and pharmacokinetic profiles can be more sensitive to formulation changes.

The FDA’s product-specific guidance should be reviewed for the relevant reference listed drug and dosage form. The guidance position can differ between immediate-release and extended-release products.[3]

What patents protect pioglitazone/metformin products?

The active-ingredient patent position is mature. Original compound patents for pioglitazone and metformin are expired in the United States, and generic competition has existed for many years. The commercial patent analysis therefore focuses on:

• Combination-product patents.
• Extended-release formulation patents.
• Manufacturing-process patents.
• Method-of-use patents.
• Orange Book-listed patents associated with the specific reference NDA.
• Patent certifications and litigation under Paragraph IV.

A live Orange Book conclusion must be tied to the exact reference product, dosage form, strength, and current listing record. Historical patent numbers should not be used as a substitute for the current FDA listing because patents may expire, be delisted, or no longer affect a particular strength.[4]

How likely are Paragraph IV challenges?

Paragraph IV risk is structurally high for mature oral combinations because:

• The active ingredients are off-patent.
• Multiple manufacturers can develop conventional tablets.
• Bioequivalence pathways are established.
• Manufacturing processes are widely available.
• Commercial value comes from scale and channel access rather than exclusivity.

The principal barriers are extended-release bioequivalence, tablet-size management, low-dose content uniformity, and formulation-specific patent claims. A generic applicant may pursue a Paragraph IV certification where a listed patent is considered invalid, unenforceable, or not infringed. Litigation exposure is more likely around formulation or combination claims than around the expired active ingredients.

What is the Orange Book status and exclusivity outlook?

The product category has no meaningful new chemical entity exclusivity remaining. Any U.S. exclusivity opportunity would arise from a new formulation, new indication, pediatric development, or another qualifying regulatory innovation rather than from the original active ingredients.

Exclusivity type	Relevance to this product category
New chemical entity exclusivity	Not available for mature pioglitazone or metformin
Five-year NCE exclusivity	Expired or inapplicable
Three-year clinical-investigation exclusivity	Possible only for qualifying new clinical work and approval
Pediatric exclusivity	Product- and study-specific; not assumed
Orphan exclusivity	Not relevant to the broad type 2 diabetes indication
Patent term extension	Historical product-specific issue; no general current opportunity
Formulation patent term	Depends on claim scope, validity, and Orange Book listing

What manufacturing and intellectual-property barriers affect market entry?

Manufacturing barriers are manageable for immediate-release tablets but more material for extended-release products.

The most important barriers are:

1. Achieving low-dose pioglitazone uniformity across a high-dose metformin matrix.
2. Controlling metformin dissolution after changes in compaction, lubricant level, or polymer grade.
3. Maintaining tablet dimensions within acceptable swallowability limits.
4. Demonstrating robust bioequivalence under fed and fasting conditions.
5. Controlling nitrosamine risk in metformin products and their excipient supply chains.
6. Establishing consistent quality across multiple metformin and pioglitazone suppliers.

Metformin products require a documented nitrosamine-control strategy. The FDA has identified nitrosamine contamination as a quality issue affecting some metformin products and has recommended risk assessment, testing, and appropriate manufacturing controls.[5]

Excipient suppliers should be qualified for residual solvents, elemental impurities, microbial quality, peroxide levels, and nitrosamine-related risk where applicable. Povidone, crospovidone, cellulose derivatives, and lubricant systems can vary by grade and supplier, making vendor changes potentially relevant to dissolution and process performance.

Which commercial opportunities are strongest?

Low-cost immediate-release fixed-dose combinations

This is the lowest technical-risk opportunity. The value proposition is tablet consolidation and lower cost relative to two separate medicines. Success depends on manufacturing efficiency, tender access, and distribution in price-sensitive markets.

Extended-release combinations

Extended-release products offer greater differentiation. They can target once-daily dosing, tablet-burden reduction, and metformin tolerability. The development program is more expensive, but the product may support better pricing and broader prescriber differentiation than a basic immediate-release generic.

Market-specific strengths

Some countries use strengths or dosing conventions that differ from the United States. Region-specific strength development can create opportunities in public procurement markets, provided the dosage form has a clear regulatory pathway and adequate demand.

Combination products for emerging markets

Pioglitazone/metformin remains relevant in countries with high diabetes prevalence and constrained access to newer therapies. Commercial opportunities are strongest where:

• Generic substitution is established.
• Metformin remains a first-line treatment.
• SGLT2 and GLP-1 products have limited reimbursement.
• Fixed-dose combinations receive procurement preference.
• Local manufacturing or regional supply is valued.

Excipient-led product differentiation

Excipient innovation can support a defensible product without relying on a new active ingredient. Potential claims or commercial differentiators include:

• Reduced tablet size.
• Improved dissolution consistency.
• Controlled-release matrix architecture.
• Lower friability at high drug loading.
• Improved moisture protection.
• Reduced gastrointestinal intolerance through release modulation.
• Continuous-manufacturing compatibility.
• Reduced dependence on a single excipient supplier.

These concepts must be supported by comparative performance and, where applicable, patent claims that cover the formulation rather than merely listing conventional excipients.

How does pioglitazone/metformin compare with newer diabetes combinations?

Attribute	Pioglitazone/metformin	Metformin/SGLT2 inhibitor	Metformin/DPP-4 inhibitor	Metformin/GLP-1 product
Active-ingredient maturity	High	Mixed	Mixed	Mixed
Cost potential	Strong	Moderate to weak	Moderate	Weak to moderate
Weight effect	May increase weight	Often weight reduction	Generally weight neutral	Weight reduction
Heart-failure positioning	Pioglitazone carries a boxed warning	Some agents have cardiovascular and renal benefits	Agent-specific	Agent-specific
Formulation complexity	Moderate	Moderate	Moderate	High for injectable or specialized products
Generic competition	Established	Growing	Established for some products	More limited
Best commercial strategy	Cost and convenience	Outcomes and reimbursement	Tolerability and convenience	Clinical differentiation

The combination is unlikely to win on modern cardiovascular or weight-management claims. Its commercial position rests on affordability, broad manufacturing capability, and fixed-dose convenience.

What litigation and settlement issues should companies monitor?

Litigation risk should be assessed at the individual product level rather than assumed from the drug class. Key issues include:

• ANDA Paragraph IV notices involving extended-release or combination patents.
• Patent infringement claims based on matrix composition or release profiles.
• Settlements involving launch dates, authorized generics, or licensing rights.
• Regulatory litigation over reference-listed-drug designation or bioequivalence requirements.
• Product-liability claims related to pioglitazone-associated heart failure, bladder cancer allegations, fractures, and edema.

A generic entrant should separate three risks: patent launch risk, FDA approval risk, and post-launch product-liability risk. For this mature category, FDA and manufacturing execution may be more consequential than core active-ingredient patent barriers.

Key Takeaways

• Pioglitazone hydrochloride and metformin hydrochloride are mature, off-patent small molecules with established generic competition.
• Metformin drives tablet mass, flow, compressibility, dissolution, and gastrointestinal tolerability requirements.
• Pioglitazone creates low-dose content-uniformity and segregation risks.
• Immediate-release products offer the lowest development and manufacturing risk.
• Extended-release and bilayer tablets offer stronger differentiation but require more complex bioequivalence and process development.
• The most valuable excipient strategies involve matrix control, particle distribution, tablet-size reduction, and manufacturing robustness.
• Nitrosamine controls, excipient supplier qualification, and dissolution consistency are material quality requirements.
• Patent opportunities are more likely to involve formulation, process, or method-of-use claims than active-ingredient claims.
• Biosimilar risk is not relevant because both ingredients are chemically synthesized small molecules.
• Commercial success depends on cost, procurement access, fixed-dose convenience, and regional demand rather than broad exclusivity.

FAQs About Pioglitazone/Metformin Excipient and Commercial Strategy

Can pioglitazone and metformin be manufactured in one immediate-release tablet?

Yes. Immediate-release fixed-dose tablets are established products. The key development issue is maintaining pioglitazone content uniformity within a high-dose metformin formulation.

Which polymer is most commonly considered for extended-release metformin?

Hypromellose is a leading option because it forms a controllable hydrophilic matrix. Grade, viscosity, concentration, compression force, and tablet porosity must be optimized together.

Is a bilayer tablet commercially superior to a single-layer tablet?

Not automatically. A bilayer tablet can improve separation of formulation functions but adds equipment, process-validation, and delamination risk. A single-layer matrix is usually simpler and less expensive.

Are biosimilar regulations relevant to this combination?

No. Pioglitazone hydrochloride and metformin hydrochloride are small-molecule active ingredients. Generic drug requirements, including ANDA and bioequivalence standards, apply instead.

What is the strongest near-term commercial opportunity?

A cost-optimized fixed-dose immediate-release product is the lowest-risk opportunity. An extended-release formulation has greater differentiation potential but requires higher development investment and carries greater bioequivalence risk.

References

1. U.S. Food and Drug Administration. (2023). Actoplus Met and Actoplus Met XR prescribing information. FDA/DailyMed.

2. U.S. Food and Drug Administration. (2013). Abbreviated new drug application submissions: Refuse-to-receive standards. FDA.

3. U.S. Food and Drug Administration. (n.d.). Product-specific guidances for generic drug development. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

5. U.S. Food and Drug Administration. (2024). Control of nitrosamine impurities in human drugs: Guidance for industry. FDA.

6. International Council for Harmonisation. (2009). ICH Q8(R2): Pharmaceutical development. ICH.

7. International Council for Harmonisation. (2005). ICH Q9: Quality risk management. ICH.